Hyperrab

Human Rabies Immunoglobulin, the active ingredient in Hyperrab, is an Immunoglobulin presented as a sterile solution for injection for intramuscular use. It supplies anti‑rabies antibodies that provide passive immunity for post‑exposure prophylaxis of rabies in individuals who have been potentially exposed to the virus.

GNH USA supplies Hyperrab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing cold‑chain logistics to ensure product integrity during global distribution.

Hyperrab, a human rabies immunoglobulin, is used in the post‑exposure prophylaxis pathway for rabies.

- Post‑exposure prophylaxis of rabies: Provides immediate passive immunity to neutralize virus after a potential animal bite or exposure. - Adjunct to rabies vaccine: Enhances early protection when administered together with the active rabies vaccine series. - High‑risk wound management: Supplies antibodies to prevent viral entry in severe or contaminated bite wounds.

Adverse reactions to Hyperrab are generally related to its immunoglobulin nature and the injection route.

Common Side Effects: - Injection site pain: Mild to moderate discomfort at the site of administration. - Redness or swelling: Localized erythema or edema. - Fever or chills: Transient systemic reaction. - Headache: Mild headache occurring within hours. - Nausea: Occasional mild nausea.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate medical attention. - Serum sickness: Immune complex–mediated reaction with fever, rash, and arthralgia. - Aseptic meningitis: Rare inflammation of the meninges without infection. - Hemolysis: Destruction of red blood cells in susceptible individuals. - Renal impairment: Acute kidney injury in rare cases.

When using Hyperrab, consider the following safety measures.

- Allergy assessment: Verify no prior severe reaction to human immunoglobulins. - Pregnancy: Use only if the potential benefit justifies the unknown risk. - Breastfeeding: Caution advised; limited data on excretion in milk. - Concurrent vaccines: Administer rabies vaccine according to schedule; avoid other live vaccines simultaneously. - Immunocompromised patients: Monitor for reduced efficacy and possible infections. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Hyperrab may interact with other products or therapies.

Major Interactions (Avoid): - Concurrent administration of other immunoglobulin products: May interfere with antibody levels. - Blood products with high IgG content: Can affect serological testing and efficacy. - Live viral vaccines: May reduce vaccine efficacy if given at the same time.

Moderate Interactions (Monitor Closely): - Antihistamines: May mask mild allergic reactions, requiring careful observation. - Immunosuppressants: May diminish the passive immunity provided by the immunoglobulin.